[Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]., Morita Yuka;Yagi Yu;Kanemasa Yusuke;Sasaki Yuki;Ishimine Kento;Hayashi Yudai;Mino Mano;Ohigashi An;Tamura Taichi;Nakamura Shohei;Okuya Toshihiro;Shimizuguchi Takuya;Shingai Naoki;Toya Takashi;Shimizu Hiroaki;Najima Yuho;Kobayashi Takeshi;Haraguchi Kyoko;Doki Noriko;Okuyama Yoshiki;Ohashi Kazuteru;Shimoyama Tatsu, [Rinsho ketsueki] The Japanese journal of clinical hematology, 64(7), 586-595, 2023年